Method Validation by CPTAC Guidelines for Multi-protein Marker Assays Using Multiple Reaction Monitoring-mass Spectrometry

Son, Minsoo; Kim, Hyunsoo; Yeo, In Wook; Kim, Yoseop; Sohn, Areum; Kim, Youngsoo

doi:10.1007/s12257-018-0454-7

Cited by 3 publications

(2 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NCI CPTAC flagship programs have been largely successful in developing assays and potential markers across multiple cancers, leveraging the proteogenomic approach ( 38 , 70 , 71 , 72 ). As of 2022, over 3500 assays for 3224 unique peptides and 1742 unique proteins have been validated by the CPTAC initiative to develop reproducible targeted mass spectrometry–based assays for biomarkers in cancer ( 73 , 74 , 75 ). Advances in NGS will allow for ever-better identification of proteins to create pipelines of interest to both CPTAC and the industry.…”

Section: Technology Advances Promise Biomarker Success—but To Date a ...mentioning

confidence: 99%

An Inflection Point in Cancer Protein Biomarkers: What was and What's Next

Barker

Alba

Mallick

et al. 2023

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Section: Technology Advances Promise Biomarker Success—but To Date a ...mentioning

confidence: 99%

An Inflection Point in Cancer Protein Biomarkers: What was and What's Next

Barker

Alba

Mallick

et al. 2023

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

“…The not fully realized potential of targeted proteomics may represent a lack of tools and expertise for the steps of targeted assay development, including sample preparation and data analysis. However, new tools to simplify and standardize sample preparation through enhanced sample clean‐up and automation, as well as to automate and enhance key steps such as peptide selection and predicting fragment ion spectra, the decreasing cost of peptide synthesis, and the availability of public repositories of standardized targeted assays may help to better equip researchers to utilize targeted MS assays. User‐friendly assay kits may also help to fill this gap, while supporting quality control and standardization .…”

Section: Trends In Proteomics‐based Biomarker Developmentmentioning

confidence: 99%

Targeted and Untargeted Proteomics Approaches in Biomarker Development

et al. 2020

View full text Add to dashboard Cite

An enormous amount of research effort has been devoted to biomarker discovery and validation. With the completion of the human genome, proteomics is now playing an increasing role in this search for new and better biomarkers. Here, what leads to successful biomarker development is reviewed and how these features may be applied in the context of proteomic biomarker research is considered. The "fit-for-purpose" approach to biomarker development suggests that untargeted proteomic approaches may be better suited for early stages of biomarker discovery, while targeted approaches are preferred for validation and implementation. A systematic screening of published biomarker articles using MS-based proteomics reveals that while both targeted and untargeted technologies are used in proteomic biomarker development, most researchers do not combine these approaches. i) The reasons for this discrepancy, (ii) how proteomic technologies can overcome technical challenges that seem to limit their translation into the clinic, and (iii) how MS can improve, complement, or replace existing clinically important assays in the future are discussed.

show abstract